Condition: Syringomyelia · Thalidomide · Sponsor: Xuanwu Hospital, Beijing
Purpose: This phase II clinical trial aims to evaluate the indications, therapeutic effects and side effects of thalidomide in refractory syringomyelia. Primary outcome measure: The primary endpoint is the change of ASIA at week 12. The clinical efficacy is defined as ASIA increase ≥ 1 at week 12, as compared with that before thalidomide usage.
This description comes directly from the study's public registry record.
fengzeng jian · +861083198899 · jianfengzeng@xwh.ccmu.edu.cn
chenghua yuan · +861083198899 · yuanchenghua@ccmu.edu.cn
Always discuss trial participation with your own doctor first.
| Fengzeng Jian | Beijing, Beijing City, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06268093